The NGS-PTL project aims at developing and validating research, diagnostic and prognostic approaches to leukemia based on the most innovative massive parallel DNA/RNA sequencing technologies.
The main objectives of the project are thus the following:
- to develop a European Hematological/NGS network of physicians and scientists;
- to discover novel insights into the mechanisms involved in leukemogenesis and to develop genetic models that accurately define novel leukemia subtypes based on the genomic profile of individual patients;
- to develop biostatistic and bioinformatic tools for coupling scientific research data with clinical/molecular databases;
- to develop “leukemia diagnostic panels” to drive personalized treatments and tailor therapies to different stratified groups of leukemia patients.
The NGS-PTL project results are expected to accomplish the objectives for personalized medicine advised by the current FP7 Programme and the next EC Horizon 2020 Programme.
In particular, the NGS-PTL project is expected to provide:
- completely new knowledge of the etiology of hematological diseases and of the causes of within patient cohorts' inter-individual variability in response to treatments;
- identification of novel diagnostic and prognostic biomarkers and/or genome-wide signatures able to allow an early diagnosis, which means a timely start of the targeted treatment;
- identification of innovative tools for patients' stratification to guide the adoption of the most suited and really effective treatment for each leukemia patient, avoiding potential short and long-term side effects.
These results will contribute to the identification and tweak of innovative tools aimed at finally including personalized medicine into routine clinical practice to provide an incisive guidance to leukaemia diagnosis, prognosis and therapeutic interventions.